| [1] |
李舜伟，李焰生，刘若卓.中国偏头痛诊断治疗指南[J].中国疼痛医学杂志, 2011, 17(2): 65-86.
|
| [2] |
中华医学会疼痛学分会头面痛学组，中国医师协会神经内科医师分会疼痛和感觉障碍专委会.中国偏头痛防治指南[J].中国疼痛医学杂志, 2016, 22(10): 721-727.
|
| [3] |
Adams AM, Serrano D, Buse DC, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) study methods and baseline results[J]. Cephalalgia, 2015, 35(7): 563-578.
|
| [4] |
Headache classification committee of the International Headache Society(IHS) the international classification of headache disorders, 3rd edition[J]. Cephalalgia, 2018, 38(1): 1-211.
|
| [5] |
Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type a as a migraine preventive treatment. For the botox migraine clinical research group[J]. Headache, 2000, 40(6): 445-450.
|
| [6] |
Blumenfeld AM, Silberstein SD, Dodick DW, et al. Insights into the functional anatomy behind the PREEMPT injection paradigm: guidance on achieving optimal outcomes[J]. Headache, 2017, 57(5): 766-777.
|
| [7] |
GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the global burden of disease study 2016[J]. Lancet Neurol, 2019, 18(5): 459-480.
|
| [8] |
Dodick DW, Loder EW, Manack Adams A, et al. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study[J]. Headache, 2016, 56(5): 821-834.
|
| [9] |
Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis[J]. Cephalalgia, 2017, 37(5): 470-485.
|
| [10] |
Gu S, Jin R. Assembly and function of the botulinum neurotoxin progenitor complex[J]. Curr Top Microbiol Immunol, 2013, 364: 21-44.
|
| [11] |
Blumenfeld AM, Stark RJ, Freeman MC, et al. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study[J]. J Headache Pain, 2018, 5, 19(1): 13.
|
| [12] |
Restani L, Antonucci F, Gianfranceschi L, et al. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A)[J]. J Neurosci, 2011, 31(44): 15650-15659.
|
| [13] |
Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy[J]. Headache, 2004, 44(1): 35-42; discussion 42-43.
|
| [14] |
Cui M, Khanijou S, Rubino J, et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain[J]. Pain, 2004, 107(1-2): 125-133.
|
| [15] |
Drinovac V, Bach-Rojecky L, Lacković Z. Association of antinociceptive action of botulinum toxin type A with GABA-A receptor[J]. J Neural Transm (Vienna), 2014, 121(6): 665-669.
|
| [16] |
Drinovac Vlah V, Bach-Rojecky L, Lacković Z. Antinociceptive action of botulinum toxin type A in carrageenan-induced mirror pain[J]. J Neural Transm (Vienna), 2016, 123(12): 1403-1413.
|
| [17] |
Voller B, Sycha T, Gustorff B, et al. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A[J]. Neurology, 2003, 61(7): 940-944.
|
| [18] |
Burstein R, Zhang X, Levy D, et al. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains[J]. Cephalalgia, 2014, 34(11): 853-869.
|
| [19] |
Melo-Carrillo A, Strassman AM, Nir RR, et al. Fremanezumab-A humanized monoclonal anti-CGRP antibody-inhibits thinly myelinated (Aδ) but not unmyelinated (C) meningeal nociceptors[J]. J Neurosci, 2017, 37(44): 10587-10596.
|
| [20] |
Blumenfeld A, Silberstein SD, Dodick DW, et al. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program[J]. Headache, 2010, 50(9): 1406-1418.
|
| [21] |
Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies[J]. Headache, 2015, 55(1): 3-20.
|
| [22] |
Masters-Israilov A, Robbins MS. OnabotulinumtoxinA wear-off phenomenon in the treatment of chronic migraine[J]. Headache, 2019, 59(10): 1753-1761.
|
| [23] |
Freund B, Rao A. Efficacy of botulinum toxin in tension-type headaches: a systematic review of the literature[J]. Pain Pract, 2019, 19(5): 541-551.
|
| [24] |
Yuan H, Silberstein SD. The use of botulinum toxin in the management of headache disorders[J]. Handb Exp Pharmacol, 2021, 263: 227-249.
|